Tenofovir 147127-20-6

.cp_wz table {border-top: 1px solid #ccc;border-left:1px solid #ccc; } .cp_wz table td{border-right: 1px solid #ccc; border-bottom: 1px solid #ccc; padding: 5px 0px 0px 5px;} .cp_wz table th {border-right: 1px solid #ccc;border-bottom: 1px solid #ccc; padding: 5px 0px 0px 5px;}


Molecular Weight:

287.21 Tenofovir blocks reverse transcriptase and hepatitis B virus infections.

Biological Activity

Tenofovir reduces the viral cytopathic effect of HIV-1(IIIB), HIV-2(ROD)
and HIV(EHO) with EC50 of 1.15 μg/mL, 1.12 μg/mL and 1.05 μg/mL in MT-4
cells. Tenofovir also reduces the viral cytopathic effect of
SIV(mac251) , SIV(B670) ,SHIV(89.6) and SHIV(RTSHIV). Tenofovir is uniquely active against multinucleoside-resistant HIV
expressing the Q151M mutation, but shows reduced susceptibility to the
T69S insertion mutations.


Tenofovir inhibits hepatitis B virus (HBV) activity in HepG2 2.2.15, HepAD38 and HepAD79 cells. Tenofovir (4 μM) completely inhibits the growth of HIVIIIB in MT-2
cells. Tenofovir inhibits synthesis of negative strand strong-stop DNA
with IC50 of 9 µM for wild-type RT, 6 µM for M184V RT and 50 µM for K65R
RT.


Tenofovir (30 mg/kg) completely prevents SIV infection in all macaques
without toxicity. Tenofovir treatment reduces plasma viral RNA levels to
undetectable, with parallel decreases in the infectivity of plasma and
infectious cells in peripheral blood mononuclear cells and cerebrospinal
fluid (CSF) and stabilization of CD4+ T-cell numbers. Tenofovir (30
mg/kg, s.c.) completely abrogates HIV infection via intravaginal
exposure in pig-tailed macaques.

Contact us if you need more details on 147127-20-6. We are ready to answer your questions on packaging, logistics, certification or any other aspects about Tenofovir 147127-20-6、147127-20-6 Tenofovir. If these products fail to match your need, please contact us and we would like to provide relevant information.

Product Categories : Microbiology > Reverse Transcriptase Inhibitor